Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE

By afschroeder • March 31, 2026

Kileel EM, Malvestutto CD, Zanni MV, Davies-Smith E, Fichtenbaum CJ, Lake JE, Lo J, Aberg JA, Martinez E, Patel K, Bloomfield GS, Chu SM, Awwad A, Diggs MR, Lu AB, Bares SH, Berrner D, Smieja M, Okeke NL, Kumar P, João E, Currier JS, Lu MT, Fox MP, Brennan AT, Douglas PS, Grinspoon SK, Ribaudo HJ. Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE. Lancet HIV. 2026 Mar 27:S2352-3018(25)00354-6. doi: 10.1016/S2352-3018(25)00354-6. Epub ahead of print. PMID: 41911941.

Tags: Infectious Diseases, Publications

Cefepime and Mortality-A Dosing Problem, Not a Drug Problem

Uslan DZ, Smith EA. Cefepime and Mortality-A Dosing Problem, Not a Drug Problem. JAMA Netw Open. 2026 Sep 1;9(9):e2632904. doi: 10.1001/jamanetworkopen.2026.32904. PMID: 42720957.

Immunotherapy for invasive Candida infections: Translating host-directed strategies into clinical practice

Sprute R, Singh S, Conti HR, Cornely OA, van de Veerdonk FL, Carvalho A, Ibrahim AS. Immunotherapy for invasive Candida infections: Translating host-directed strategies into[...]

Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis

Hoffman R, Watanabe M, Martínez E, Zanni MV, Pozniak A, Shakil SS, McCallum S, Chu SM, Srinivasa S, Malvestutto CD, Fichtenbaum CJ, Bloomfield GS, Lu[...]